Stavudine (d4T, Zerit)

Overview | News | Research

Overview

Prescribing Information for Stavudine (d4T, Zerit) (PDF) (January 2012)
From Bristol-Myers Squibb Company
Drug Interactions: Stavudine (August 2004)
From Project Inform

News

d4T -- Time to Move On (November/December 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
Blog Examines Use of Controversial HIV Drug in Malawi (August 16, 2012)
In Kaiser Daily Global Health Policy Report, from Henry J. Kaiser Family Foundation
Activists Oppose Gates Foundation Funding Study Using Low-Dose d4T (January/February 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
Why It's Time to Say Goodbye to Stavudine ... Everywhere (2012)
A group of prominent HIV/AIDS activists and experts argue against any attempt to encourage greater use of Zerit (stavudine).
In Southern African Journal of HIV Medicine
European Medicines Agency Issues Restricted Indication for d4T (Stavudine) (March/April 2011)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
New Labeling for Zerit Capsules and Zerit for Oral Solution (December 10, 2010)
From U.S. Food and Drug Administration
New WHO Guidelines Urge Phase-Out of Major HIV Drug (December 1, 2009)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
FDA Approval of Three Generic Stavudine Formulations (December 30, 2008)
From U.S. Food and Drug Administration
FDA Tentatively Approves Generic Pediatric d4T for PEPFAR (December 22, 2005)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
Efavirenz, Stavudine Demand May Soon Exceed Supply in Developing World (March 4, 2005)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation

VIEW ALL ARTICLES

Research

Clinical Trials Using Stavudine (Regularly Updated)
U.S. and international trials currently recruiting.
From U.S. National Institutes of Health
Rapid Drop in Mitochondria in Fat Biopsies Within Four Weeks of d4T Use (November/December 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
High Prevalence of Peripheral Neuropathy in Children Taking d4T in Rural South Africa (July/August 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
Dose-Ranging, Randomized, Clinical Trial of Atazanavir With Lamivudine and Stavudine in Antiretroviral-Naive Subjects: 48-Week Results
In AIDS
High Prevalence of d4T-Associated Lipodystrophy Including Lipoatrophy in Children (March/April 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
Lipoatrophy Common in Children Receiving d4t in South Africa (March 7, 2012)
From aidsmap.com
d4T Toxicity Risk 7-Fold Higher When Started With TB Treatment (June 18, 2009)
From aidsmap.com
HIV JournalView: Study Ties Insulin Resistance to NRTIs, Not PIs (September 2005)
d4T and 3TC are associated with insulin resistance and high insulin levels; indinavir is associated only with elevated insulin levels; and no link to insulin abnormalities is found for AZT or ddI.
From TheBodyPRO.com
Abacavir Is Not Associated With the Metabolic Changes Seen in Patients Treated With Stavudine (February 24, 2005)
In The 12th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
Both Tenofovir and Stavudine Well Tolerated in HCV-Coinfected Patients (July 12, 2004)
In The XV International AIDS Conference, from TheBodyPRO.com

VIEW ALL ARTICLES

MOST VIEWED ARTICLES

	HIV Management Today: Mental Health & HIV, the Uncharted Territory
	Danish Study Targets HIV Reservoir, in Latest Search for HIV Cure
	CROI 2013: Research on Aging and HIV (Video)
	PrEP Failures and Successes: One Study Whose Impact Will Last Well Beyond CROI 2013
	10 Top Studies Whose Impact Will Last Well Beyond CROI 2013
	HIV Opportunistic Infection Guidelines Updated

More Most Viewed Articles

TheBodyPRO.com is a service of Remedy Health Media, LLC, 500 5th Avenue, 19th Floor, New York, NY 10110. TheBodyPRO.com and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of TheBodyPRO.com's homepage, topic pages, page designs and HTML code. General Disclaimer: TheBodyPRO.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBodyPRO.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.